RxDoctor Payments Data

Maekal Elyasi, DO

Internal Medicine · Manhasset, NYNPI 1821441890

Payments from drug & device makers

$1,660in general payments, 2019–2025

Across 15 payments — averaging $110.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$1K
  • Abbott$286
  • Amgen$138
  • Johnson & Johnson$125
  • Philips North America LLC$13

What the payments were for

  • Food & beverage$1,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,660 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$188,844
Medicare patients
501
Services billed
2,506

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide413$469,279
JardianceEmpagliflozin76$102,039
OzempicSemaglutide68$95,071
EliquisApixaban58$73,766
Ursodiol11$37,870
ProliaDenosumab21$35,300
Repatha SureclickEvolocumab41$33,444
EntrestoSacubitril/Valsartan26$30,493
XareltoRivaroxaban18$26,945
Synjardy XrEmpagliflozin/Metformin Hcl22$17,956
RybelsusSemaglutide18$17,274
FarxigaDapagliflozin Propanediol12$14,241
Hydrocortisone23$13,670
JanuviaSitagliptin Phosphate15$13,282
Breo ElliptaFluticasone/Vilanterol18$6,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$1,098$119,99598 claims
AmgenProlia$138$35,30021 claims
Johnson & JohnsonXarelto$125$26,94518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manhasset

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →